Clinical Trials

Phase 3 Active not recruiting

Breast Neoplasms

NCT02115282 2026-05-29

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

608 enrolled 18 charts

Breast Neoplasms

NCT05582499 2026-05-28

FASCINATE-N

716 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05870579 2026-05-27

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Phase 1 Recruiting

48 enrolled

Breast Neoplasms

NCT06953882 2026-05-26

SELECT

140 enrolled

Phase 2 Not yet recruiting

HER2 Negative Breast Cancer

NCT07287098 2026-05-22

preEMBER

600 enrolled

Phase 1/2 Not yet recruiting

Breast Neoplasms

NCT07596212 2026-05-19

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

100 enrolled

BreastOther

Breast Neoplasms, Sexual Dysfunctions, Psychological

NCT05085002 2026-05-14

A Study of Lerociclib in Participants With Advanced Breast Cancer

Phase 2 Terminated

100 enrolled 14 charts

Phase 4 Active not recruiting

Advanced Breast Cancer

NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

134 enrolled

Breast Neoplasms

NCT04293393 2026-03-12

CARABELA

200 enrolled 27 charts

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07460752 2026-03-10

Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients

98 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT06348134 2026-02-17

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

74 enrolled

Breast Neoplasms

NCT07158021 2026-02-13

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial

75 enrolled

Breast Neoplasms

NCT02624973 2026-02-12

PETREMAC

200 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT01674140 2026-02-10

e3

1,939 enrolled 15 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT03056755 2026-01-13

BYLieve

383 enrolled 16 charts

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT05122377 2026-01-06

RWE About QOL and Compliance of Patients With OFS in China

Completed

562 enrolled

Breast Neoplasms, Patient Compliance

NCT01723774 2025-12-09

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

84 enrolled 17 charts

Breast Neoplasms

NCT03671330 2025-10-31

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

327 enrolled

Breast Neoplasms

NCT05607004 2025-10-30

EVANGELINE

87 enrolled

Breast Neoplasms

NCT03822468 2025-10-16

AMALEE

376 enrolled 17 charts

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07179939 2025-09-18

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

288 enrolled

HER2-positive Breast Cancer

NCT04478266 2025-09-11

AMEERA-5

Phase 3 Terminated

1,068 enrolled 21 charts

Breast Neoplasms

NCT02003209 2025-08-08

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

315 enrolled 11 charts

Breast Neoplasms

NCT02476786 2025-07-28

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

50 enrolled

Breast Neoplasms

NCT03944434 2025-02-26

FACILE

116 enrolled

Breast Neoplasms

NCT03936933 2025-02-17

Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer

Phase 3 Terminated

6 enrolled

Breast Neoplasms

NCT02430103 2024-12-12

Study of Preservation of Ovarian Reserve During Chemotherapy for Young Breast Cancer Patients

Active not recruiting

349 enrolled

Breast Neoplasms

NCT03839823 2024-10-09

RIGHT Choice

222 enrolled 17 charts

Breast Neoplasms

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

620 enrolled

Breast Neoplasms

NCT05163106 2024-08-02

NEOLETRIB

85 enrolled

Breast Neoplasms

NCT04862143 2024-06-20

TELEPIK

Phase 2 Terminated

2 enrolled 10 charts

Advanced Breast Cancer

NCT05720260 2024-06-10

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

42 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

271 enrolled

Breast Neoplasms

NCT03272477 2024-04-17

TP-II

257 enrolled

Breast Neoplasms

NCT03423199 2024-03-22

PATHWAY

Phase 3 Unknown

180 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT03007979 2024-03-20

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

55 enrolled 15 charts

Breast Neoplasms

NCT00295646 2024-03-15

Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid

1,803 enrolled 20 charts

Breast Neoplasms

NCT02278120 2024-03-12

MONALEESA-7

672 enrolled 16 charts 1 FDA

Advanced Metastatic Breast Cancer

NCT03664895 2023-12-04

Density Lowering Effect of "OFS Add on to TMX"(DELFINO Trial)

Phase 3 Unknown

224 enrolled

Breast Cancer Invasive

NCT02941926 2023-10-24

COMPLEEMENT-1

3,246 enrolled 11 charts

Breast Neoplasms

NCT00309478 2023-06-29

Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients

1,099 enrolled

Breast Neoplasms

NCT02333370 2023-06-08

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Phase 1 Completed

88 enrolled

Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

NCT05110170 2023-05-16

Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®

188 enrolled

Breast Neoplasms

NCT05800197 2023-04-06

NEMO

Unknown

300 enrolled

Breast Neoplasms

NCT00432172 2023-04-03

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

189 enrolled 17 charts

Breast Neoplasms

NCT03447132 2023-03-10

SAFIA

354 enrolled

Breast Neoplasms

NCT02914158 2023-01-17

ASPAIT

Phase 3 Unknown

680 enrolled

Breast Neoplasms

NCT01989780 2022-08-04

BOOSTER

160 enrolled